Overview of monoclonal antibodies in cancer therapy: present and promise
M Stern, R Herrmann - Critical reviews in oncology/hematology, 2005 - Elsevier
After 30 years of development, therapy with monoclonal antibodies has started to realize its
promise. Clinical use is most widespread in the field of oncology, where half of the agents …
promise. Clinical use is most widespread in the field of oncology, where half of the agents …
Rituximab therapy in malignant lymphoma
B Coiffier - Oncogene, 2007 - nature.com
Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell
lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL) …
lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL) …
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized …
CH Geisler, A Kolstad, A Laurell… - Blood, The Journal …, 2008 - ashpublications.org
Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with
stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL …
stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL …
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free …
M Dreyling, G Lenz, E Hoster, A Van Hoof… - Blood, 2005 - ashpublications.org
Mantle-cell lymphoma (MCL) is characterized by poor prognosis with a median survival of
only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a …
only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a …
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure …
G Lenz, M Dreyling, E Hoster, B Wörmann… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an …
moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an …
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
V Fernàndez, O Salamero, B Espinet, F Solé, C Royo… - Cancer research, 2010 - AACR
Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but
some cases display an indolent behavior that might not necessitate treatment at diagnosis …
some cases display an indolent behavior that might not necessitate treatment at diagnosis …
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus …
JE Romaguera, L Fayad, MA Rodriguez… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To determine the response, failure-free survival (FFS), and overall survival rates
and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously …
and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously …
[HTML][HTML] ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
To complement the existing treatment guidelines for all tumour types, ESMO organizes
consensus conferences to focus on specific issues in each type of tumour. In this setting, a …
consensus conferences to focus on specific issues in each type of tumour. In this setting, a …
Outcome of deferred initial therapy in mantle-cell lymphoma
P Martin, A Chadburn, P Christos, K Weil… - Journal of clinical …, 2009 - ascopubs.org
Purpose Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are
commonly treated immediately at diagnosis. Because data on observation, or “watch and …
commonly treated immediately at diagnosis. Because data on observation, or “watch and …
Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem …
CH Geisler, A Kolstad, A Laurell… - British journal of …, 2012 - Wiley Online Library
Mantle cell lymphoma (MCL) is a heterogenic non‐Hodgkin lymphoma entity, with a median
survival of about 5 years. In 2008 we reported the early–based on the median observation …
survival of about 5 years. In 2008 we reported the early–based on the median observation …